Clinical trials in patients with glioblastoma have demonstrated that H-1PV suppresses the activity of regulatory T cells (Treg) and promotes immune cell activation (CD8+- and CD4+- T lymphocytes as well as tumor associated macrophages) as indicated by increasing serum levels of perforin, granzyme B, IFNγ, and IL-2 (11–14). This evidence concerns the gene CD8A and neoplasm.